CJ Bioscience
Key metrics
Earnings
| Revenue, Q3 2026 | ₩863m |
|---|---|
| Revenue QoQ | -4.0% |
| Revenue YoY | +16.9% |
| Operating income, Q3 2026 | -₩4.9bn |
| Operating income QoQ | +23.0% |
| Operating income YoY | +18.9% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 3 |
|---|---|
| DART filings, previous 3 months | 4 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
No insider transactions in the last 12 months.
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩3.7bn | -₩24.8bn |
| 2024 | ₩3.5bn | -₩34.2bn |
| 2023 | ₩5.6bn | -₩32.1bn |
Filing timeline
-
CJ Bioscience to acquire remaining EzBiome, Inc. (US) shares for ₩7.6bn
CJ Bioscience filed to acquire 185,667 shares of EzBiome, Inc. (US) for ₩7.6bn, equal to 14.1% of its equity, which would raise its stake to 100.0%. The expected date is Nov 23, 2026, and the stated purpose is repayment of subsidiary borrowings and liquidation. By our calculation, the deal amount is 204.5% of FY2025 revenue.